Advanced prostatic carcinoma
Adult: 560-840 mg daily in divided doses, adjusted to between 140 mg and 1.4 g daily according to response and GI tolerance. Should be treated for at least 30-90 days before assessing the benefits of the treatment.
|Active thrombophloebitis or thromboembolic disorders. Hypersensitivity.
Warnings / Precautions
|Diabetes mellitus, CHF, epilepsy, hypertension, migraine, hepatic impairment. Increased risk of thrombosis and myocardial infarction. May exacerbate fluid retention. May affect the metabolism of calcium and phosphorus. Monitor hepatic function and bilirubin level regularly and for at least 2 mth after treatment withdrawal. Pregnancy.
|Gynaecomastia, fluid retention and CV effects, GI disturbances, hepatic dysfunction, loss of libido, hypersensitivity reactions and occasionally leucopaenia and thrombocytopaenia.
|Certain endocrine and liver function tests may be affected. May depress testosterone levels.
|Milk, dairy products or calcium-containing foods may impair oral absorption. To be taken at least 1 hr before or 2 hrs after meals.
Mechanism of Actions
|Estramustine is a combination of oestradiol and normustine which readily dephosphorylates during absorption to give estramustine, oestrone analog, oestradiol and oestrone. The oestrodiols released facilitate the uptake of the alkylating agent into the prostate cancer cells which inhibits microtubule assembly. Its effects are weaker than most alkylating agents and oestradiols.
|L01XX11 - estramustine ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Estramustine Containing Brands
Estramustine is used in following diseases
Drug - Drug Interactions of Estramustine
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor